Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis.
direct-acting antivirals
hepatic fibrosis
hepatitis C virus
insulin resistance
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Aug 2020
21 Aug 2020
Historique:
received:
13
07
2020
revised:
13
08
2020
accepted:
14
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
Chronic hepatitis C virus (HCV) infections are causally linked with metabolic comorbidities such as insulin resistance, hepatic steatosis, and dyslipidemia. However, the clinical impact of HCV eradication achieved by direct-acting antivirals (DAAs) on glucose and lipid homeostasis is still controversial. The study aimed to prospectively investigate whether antiviral therapy of HCV with DAAs alters glucose and lipid parameters. 50 patients with chronic HCV who were treated with DAAs were screened, and 49 were enrolled in the study. Biochemical and virological data, as well as noninvasive liver fibrosis parameters, were prospectively collected at baseline, at the end of treatment (EOT) and 12 and 24 weeks post-treatment. 45 of 46 patients achieved sustained virologic response (SVR). The prevalence of insulin resistance (HOMA-IR) after HCV clearance was significantly lower, compared to baseline (5.3 ± 6.1 to 2.5 ± 1.9, Viral eradication following DAA therapy may have beneficial effects on glucose homeostasis, whereas lipid profile seems to be worsened.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic hepatitis C virus (HCV) infections are causally linked with metabolic comorbidities such as insulin resistance, hepatic steatosis, and dyslipidemia. However, the clinical impact of HCV eradication achieved by direct-acting antivirals (DAAs) on glucose and lipid homeostasis is still controversial. The study aimed to prospectively investigate whether antiviral therapy of HCV with DAAs alters glucose and lipid parameters.
METHODS
METHODS
50 patients with chronic HCV who were treated with DAAs were screened, and 49 were enrolled in the study. Biochemical and virological data, as well as noninvasive liver fibrosis parameters, were prospectively collected at baseline, at the end of treatment (EOT) and 12 and 24 weeks post-treatment.
RESULTS
RESULTS
45 of 46 patients achieved sustained virologic response (SVR). The prevalence of insulin resistance (HOMA-IR) after HCV clearance was significantly lower, compared to baseline (5.3 ± 6.1 to 2.5 ± 1.9,
CONCLUSION
CONCLUSIONS
Viral eradication following DAA therapy may have beneficial effects on glucose homeostasis, whereas lipid profile seems to be worsened.
Identifiants
pubmed: 32825571
pii: jcm9092702
doi: 10.3390/jcm9092702
pmc: PMC7564474
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Radiology. 2009 Aug;252(2):595-604
pubmed: 19703889
Gastroenterology. 2008 Feb;134(2):416-23
pubmed: 18164296
Lancet. 2001 Apr 7;357(9262):1069-75
pubmed: 11297957
Hepatology. 2015 Mar;61(3):790-801
pubmed: 25203718
Gastroenterology. 2011 Jan;140(1):144-52
pubmed: 20833169
Liver Int. 2009 Feb;29(2):242-7
pubmed: 18637064
Am J Pathol. 2004 Nov;165(5):1499-508
pubmed: 15509521
Ann Hepatol. 2017 Mar - Apr;16(2):215-220
pubmed: 31153414
J Viral Hepat. 2006 May;13(5):303-10
pubmed: 16637860
World J Hepatol. 2016 Jan 18;8(2):131-8
pubmed: 26807209
J Gastroenterol Hepatol. 2013 Jan;28(1):51-6
pubmed: 22989264
Hepatology. 2010 Sep;52(3):864-74
pubmed: 20568303
J Infect Dis. 2017 Dec 27;217(1):47-50
pubmed: 29161418
Hepatology. 1999 Feb;29(2):328-33
pubmed: 9918906
Liver Int. 2018 Jul;38(7):1206-1211
pubmed: 29265719
Liver Int. 2008 Mar;28(3):355-62
pubmed: 18290778
J Viral Hepat. 2018 Aug;25(8):952-958
pubmed: 29478263
J Hepatol. 2018 Aug;69(2):461-511
pubmed: 29650333
Gut. 2005 Jul;54(7):1003-8
pubmed: 15951550
Gastroenterology. 2003 Jan;124(1):97-104
pubmed: 12512034
Gut. 2012 Jan;61(1):128-34
pubmed: 21873466
Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12766-71
pubmed: 10535997
Ann Intern Med. 2000 Oct 17;133(8):592-9
pubmed: 11033586
J Hepatol. 1994 Dec;21(6):1135-9
pubmed: 7699240
J Clin Gastroenterol. 2007 Apr;41(4):416-21
pubmed: 17413613
Acta Diabetol. 2011 Dec;48(4):337-343
pubmed: 21574001
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
J Viral Hepat. 2020 Feb;27(2):188-194
pubmed: 31596996
J Gastroenterol Hepatol. 2018 Jul;33(7):1379-1382
pubmed: 29228501
Hepatology. 2008 Jun;47(6):2127-33
pubmed: 18446789
J Hepatol. 2008 Nov;49(5):831-44
pubmed: 18814931
Hepatology. 2014 Sep;60(3):807-14
pubmed: 24919583
Am J Gastroenterol. 2003 Dec;98(12):2751-6
pubmed: 14687828
Cells. 2019 Mar 15;8(3):
pubmed: 30884773
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309